Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.
about
The Tip of the Iceberg: Clinical Implications of Genomic Sequencing Projects in Head and Neck CancerCaffeic Acid phenethyl ester is a potential therapeutic agent for oral cancerCIViC databaseOral premalignancy: the roles of early detection and chemopreventionEvaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.Molecular Aspects of Head and Neck Cancer TherapyIdentification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinomaGenome stability pathways in head and neck cancersManagement of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?Laminin-binding integrin gene copy number alterations in distinct epithelial-type cancersEvidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity.Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data.Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment responsePhase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEKMMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomasClinical update on cancer: molecular oncology of head and neck cancerAdvances in the management of squamous cell carcinoma of the head and neck.Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review.Targeting the epidermal growth factor receptor for head and neck cancer chemopreventionThe phosphatase and tensin homologue deleted on chromosome 10 mediates radiosensitivity in head and neck cancer.Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck.HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia.Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancerClinical and scientific impact of human papillomavirus on head and neck cancer.Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neckEpidermal growth factor receptor copy number in potentially malignant oral disorders and oral squamous cell carcinoma: a short communication and preliminary study.EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samplesUnraveling the molecular genetics of head and neck cancer through genome-wide approachesCytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines.Emerging drugs to treat squamous cell carcinomas of the head and neck.Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.Association between phosphorylated AMP-activated protein kinase and acetyl-CoA carboxylase expression and outcome in patients with squamous cell carcinoma of the head and neck.
P2860
Q26778433-41239BAB-6A4C-47B4-A78D-1CE2074378D7Q26822487-F01EDD46-0853-46A6-823C-B3B105518AEBQ27612411-3BA987BC-0E5F-48BD-A559-D47D5A0AB43BQ27693327-3F6F69C8-6829-4D35-8EAA-F03875A0E94AQ27851592-A278BE93-F734-49B0-9F3B-D57EF056474CQ28082815-F0265027-6A97-4987-A1A9-48837E58B43DQ28385950-E62BBCBB-FA13-4543-AA6F-E1CAE55DAA90Q28391355-D7215850-29E2-42D5-A2DC-85A86B9E1BE8Q30252081-2482B0AB-E0E5-473A-9617-E520DED56876Q30489312-9CBDF390-0874-4455-9DA2-51F376676AC9Q30498197-9DA156C3-C69E-41BF-9F27-B36F7EC49E3BQ31043365-A35AA402-DFE1-4EE7-906D-DE46295A6F0FQ31162700-2D788F56-29D7-438C-A3A2-08D3E053438FQ33434648-D8171A7E-DC41-4336-AC25-35EFCA731845Q33562476-6DFA306E-98A8-4997-8EA9-2407751DC4B6Q33570512-AF8CD009-FE92-4D7F-AB27-4B70EAAE5556Q33575439-5FC66637-A1A8-494F-8215-2F1C8644DF38Q33695197-0F63B410-6E4A-4395-BF14-1C71DEB7B276Q33720431-8B9338A7-A75A-4F4B-971D-B82A1877E2BDQ33770030-3649F197-91BB-422A-853A-475F417852F1Q33875694-FFA040AB-458C-4AD1-A72D-24B906C0FC92Q33906083-6029EDEC-C4B7-40DC-847D-E04BA2951EF4Q33916035-7D1D2860-5447-4C84-ACC3-8E340F9AFBC2Q33947789-E3A9573D-3790-437A-990D-A6ACBA082BFBQ33976619-C2FC14F0-2D1A-49B3-A4C8-C75EED278BA2Q33990915-9CD07DCE-27D2-419A-83A4-BBD9DADE158FQ34031281-21C38287-961D-4E6E-A1D0-DD86D6024DB7Q34098286-9D53B03B-E14D-4FD2-B35F-96ADD1EFCD60Q34125003-99CA72E2-943D-44F6-8336-68BEE39A1DC1Q34159125-ED4471E7-2840-4188-8C62-1D788D996522Q34195184-E79F2984-2EF7-45D7-8D13-7FB0C75C5693Q34618994-C37FA994-D8D0-4E5C-ADAA-48EDA4D3ED2BQ34639763-593BE826-D1A5-46F4-BFFC-F6544674DF05Q34760619-D015E4D5-E1A9-44BC-80D8-A37715FF38F3Q35025009-F53CF1A0-E237-4AF4-BE69-BB748AF2CB12Q35067562-19DBD1BF-A99E-4CF7-A3AF-AF47D4520F83Q35098322-20F17FC6-9C56-4D22-9676-7D52A211B3C5Q35102025-2454BDCD-29B9-4A76-8BC5-98F5C350AFC5Q35110418-1BA7801E-771B-4176-90A4-15FBEDFE875AQ35158141-89A2B7B6-E0BA-4949-9995-6FC28F5172FC
P2860
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Epidermal growth factor recept ...... head and neck squamous cancer.
@ast
Epidermal growth factor recept ...... head and neck squamous cancer.
@en
Epidermal growth factor recept ...... head and neck squamous cancer.
@nl
type
label
Epidermal growth factor recept ...... head and neck squamous cancer.
@ast
Epidermal growth factor recept ...... head and neck squamous cancer.
@en
Epidermal growth factor recept ...... head and neck squamous cancer.
@nl
prefLabel
Epidermal growth factor recept ...... head and neck squamous cancer.
@ast
Epidermal growth factor recept ...... head and neck squamous cancer.
@en
Epidermal growth factor recept ...... head and neck squamous cancer.
@nl
P2093
P3181
P356
P1476
Epidermal growth factor recept ...... head and neck squamous cancer.
@en
P2093
Adel K El-Naggar
Diane D Liu
Hidetoshi Kawaguchi
Hongli Tang
J Jack Lee
Jaroslav Jelinek
Jean-Pierre Issa
Stephane Temam
Wenhua Lang
P304
P3181
P356
10.1200/JCO.2006.06.6605
P407
P577
2007-06-01T00:00:00Z